Seed Round

Aerska is a biotechnology startup pioneering the development of systemically administered RNA interference (RNAi) medicines aimed at treating, delaying, and preventing diseases of the brain. The company focuses on overcoming the challenges of delivering genetic medicines across the blood-brain barrier. Aerska's innovative approach leverages cutting-edge technology to enhance the efficacy of RNAi therapies, potentially revolutionizing treatment options for neurological disorders. The startup aims to address critical unmet medical needs in the field of neurology, with a focus on conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. By utilizing advanced delivery mechanisms and proprietary formulations, Aerska is positioned to lead the next wave of breakthroughs in brain-targeted therapies.